κ阿片受体激动剂治疗尿毒症瘙痒临床研究进展  

Clinical Research Progress on Usingκ-Opioid Receptor Agonists to Treat Uremic Pruritus

作　　者：杨美 李育霈 杨钦博 苏白海[2] YANG Mei;LI Yupei;YANG Qinbo;SU Baihai(General Practice Medical Center,West China Hospital,Sichuan University,Chengdu 610041;Department of Nephrology/Kidney Research Institute,West China Hospital,Sichuan University,Chengdu 610041)

机构地区：[1]四川大学华西医院全科医学中心,成都610041 [2]四川大学华西医院肾脏内科/肾脏病研究所,成都610041

出　　处：《四川大学学报（医学版）》2024年第4期1044-1048,共5页Journal of Sichuan University(Medical Sciences)

基　　金：国家自然科学基金(No.82300848)资助。

摘　　要：尿毒症瘙痒是慢性肾脏病患者的严重并发症,发病率高,可导致患者出现抑郁情绪或睡眠障碍,严重影响患者生活质量和社会关系。近年来,越来越多的研究发现纳呋拉啡、Difelikefalin及纳布啡等κ阿片受体激动剂可显著减轻顽固性尿毒症瘙痒的症状,具有良好的安全性及有效性。本文简要概述了尿毒症瘙痒的流行病学、发病机制、临床症状及治疗策略,并详细阐述κ阿片受体激动剂纳呋拉啡、Difelikefalin及纳布啡等治疗尿毒症瘙痒临床研究进展。Uremic pruritus,a severe complication in patients with chronic kidney disease,is associated with a high prevalence.It can cause depression and sleep disorders,and seriously affect the quality of life and the social relations of patients.Recently,there is growing evidence showing thatκ-opioid receptor agonists,including nalfurafine,difelikefalin,and nalbuphine,can effectively and safely reduce itching symptoms in patients with refractory uremic pruritus.Herein,we reviewed the epidemiology,pathogenesis,clinical symptoms,and treatment strategies of uremic pruritus,and summarized in detail the progress in clinical research on the use ofκ-opioid receptor agonists,including nalfurafine,difelikefalin,and nalbuphine,in the management of patients with uremic pruritus.

关 键 词：尿毒症瘙痒 κ阿片受体激动剂 纳呋拉啡 纳布啡 

分 类 号：R692.5[医药卫生—泌尿科学]